ArticleJournal of pediatric gastroenterology and nutrition2026
Longitudinal performance of vibration controlled transient elastography in pediatric metabolic dysfunction associated steatotic liver disease.
Article in Journal of pediatric gastroenterology and nutrition, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
objectivesVibration controlled transient elastography (VCTE) is increasingly used to monitor metabolic dysfunction-associated steatotic liver disease (MASLD), yet optimal interpretation of serial controlled attenuation parameter (CAP) and liver stiffness measurements (LSMs) in children is undefined. We aimed to characterize longitudinal trends in CAP and LSM and assess whether changes in these measures reflect validated measures of disease regression or progression.
methodsLongitudinal retrospective study of youth with MASLD who underwent ≥2 VCTE studies. Disease regression and progression were defined using categorical and continuous changes in alanine aminotransferase (ALT) and gamma glutamyl transferase (GGT) previously linked to histologic improvement or worsening. Spaghetti plots illustrated trends over time, while longitudinal linear mixed-effects models and proportional odds mixed models assessed associations between CAP, LSM, and liver enzyme outcomes.
resultsThe cohort included 149 children (72% male, 43% Hispanic) with a mean age of 14 ± 4 years and a mean follow-up of 1.4 years. CAP and LSM showed marked intraindividual variability. Independent predictors of CAP change included age, body mass index (BMI) percentile, and glycated hemoglobin (HbA1c); predictors of LSM change included ALT, BMI, and HbA1c. Changes in CAP and LSM did not predict categorical outcomes of ALT and GGT reduction, however were significantly positively associated with continuous ALT and GGT outcomes, independent of BMI percentile.
conclusionsLongitudinal VCTE in pediatric MASLD has the potential to identify disease progression. The intraindividual variability of CAP and LSM may limit the ability to detect short-term regression or progression, highlighting the need for more precise noninvasive biomarkers for pediatric MASLD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.